Satellite Symposia

Hear directly from industry in these popular one-hour presentations. Check back as details are added frequently.
Note: CE Credits not offered for Satellite Symposia unless otherwise specifically noted.

Sunday, June 12


6:45–7:45 am PDT

Cerianna: Seeing Deeper into Recurrent or Metastatic Breast Cancer 
Sponsored by GE Healthcare
Speaker: Gary Ulaner, MD, PhD, FACNM, James & Pamela Muzzy Endowed Chair of Molecular Imaging & Therapy, Hoag Family Cancer Institute

Learning Objectives:

  • Understand the concept of estrogen receptor (ER) discordance
  • Realize the unique mechanism of action of Cerianna PET/CT
  • Recognize how detecting whole-body ER+ lesions may better inform clinical decisions
  • Learn about the clinical applications for Cerianna use

Important Safety Information for Cerianna™ (fluoroestradiol F 18) Injection
INDICATIONS AND USAGE: CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
Limitations of Use: Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).
CONTRAINDICATIONS: None.
ADVERSE REACTIONS: In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate < 1%: were injection-site pain and dysgeusia. To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp, a GE Healthcare Company, at +1-800-654-0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatchFor full Prescribing Information click here.


6:45–7:45 am PDT

 An early look at immune responses - How can zirconium 89-Df crefmirlimab advance our understanding?
 Sponsored by ImaginAb

Moderator:
Ian Wilson, CEO, ImaginAb
Presenters:
Mike Farwell, MD, Assistant Professor, University of Pennsylvania; Kim Margolin, MD, FASCO, Medical Director, Melanoma Program, St. John’s Cancer Institute; Kevin Maresca, Pfizer, Head of PET and Molecular Imaging
Panel Members: Professor Andrew Scott, Director, Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia and Anna Wu, Co-Founder and Chief Scientific Advisor, ImaginAb

During the session, we will lead you through the development path and potential benefits of our investigational agent zirconium 89-Df crefmirlimab and how it could help in gaining a clearer insight into CD8 + cell distribution and responses. We will present and discuss current clinical data and also provide details of our currently recruiting Phase IIb ‘iPREDICT’ trial that aims to assess the ‘predictive’ performance of zirconium 89-Df crefmirlimab in measuring clinical responses in patients. In addition, Pfizer (one of our consortium members) will present pre-clinical study data and outline how they design clinical trials using CD8 imaging. 


11:15 am–12:15 pm PDT


18F-rhPSMA-7.3, a unique investigational prostate-specific membrane antigen (PSMA)-targeted PET imaging agent for men with prostate cancer.
Sponsored by Blue Earth Diagnostics


In this session an overview of the investigational agent 18F-rhPSMA-7.3 will be provided.  The content will include an overview of the rhPSMA technology and mechanism of action, Clinical Data on Biodistribution of 18F-rhPSMA-7.3 from a Phase 1 Trial, data from a retrospective analysis on 18F-rhPSMA-7.3 in Patients with Primary Prostate Cancer and in Patients with Recurrent Prostate Cancer.  In addition to this a summary of the Phase 3 SPOTLIGHT Trial will be provided.

This program is sponsored by Blue Earth Diagnostics. No CE credits will be provided.


11:15 am–12:15 pm PDT

  Case Review Series
  Sponsored by Lantheus

Speakers: Andrei Iagaru, MD, Professor of Radiology - Nuclear Medicine, Stanford University, Stanford, CA and Steven Rowe, MD, PhD, Associate Professor of Radiology & Radiological Science, Johns Hopkins University, Baltimore, MD

In this session the panel will highlight patient cases with the following objective: Identify the role of PSMA PET/CT as a component of best practices for identifying suspected metastasis or disease recurrence in men with prostate cancer.


6:307:30 pm PDT


    Translational Cancer Imaging Research in the Era of Precision Medicine
    Sponsored by United Imaging

Speakers:
Dr. Jeffrey Yap, PhD, Research Professor in the Department of Radiology and Imaging Sciences at the University of Utah, Director of the Center for Quantitative Cancer Imaging, Member of the Experimental Therapeutics Program at the Huntsman Cancer Institute and Dr. Paul Vaska, PhD, Department of Radiology Faculty, Professor and Scientist of Biomedical Engineering, Renaissance School of Medicine at Stony Brook University


6:30–8:30 pm PDT

               


FAP Ligands for Imaging and Therapy
FAP (fibroblast activation protein) as a diagnostic and therapeutic target for radiopharmaceuticals has seen many advances in recent years. This special session will bring together researchers and industry sponsors to discuss the latest progress in this space.

Moderators:      
Professor Ken Herrmann, MD, MBA, University Hospital Essen
Professor Johannes Czernin, MD, University of California, Los Angeles

Speakers:           
Professor Frederik L. Giesel, MD, MBA, University Hospital Düsseldorf, Germany
Associate Professor Jeremie Calais, MD, MSc, University of California, Los Angeles
Professor Thomas Hope, MD, University of California, San Francisco
Robin Hallett, PhD, VP Discovery and Translational Sciences, POINT Biopharma
Sherly Mosessian, PhD, Chief Scientific Officer, SOFIE Biosciences
Elcin Zan, MD, Director, Nuclear Theranostics, New York University
Curt Wolfgang, PhD, VP, Clinical Development, Clovis Oncology

Monday, June 13

6:45–7:45 am PDT

Shooting for Mars through Accelerated Research and Development in Molecular Imaging, and Regulatory Hurdles in Getting There
Sponsored by GE Healthcare


Speakers:

  • Arman Rahmim, PhD, DABSNM, Professor of RadiologyPhysics and Biomedical Engineering, University of British Columbia (UBC)
  • Paul Evans, PhD, Head of Global R&D, Pharmaceutical Diagnostics, GE Healthcare
  • Paul Rudolf, MD, JD, Arnold & Porter, Senior Counsel/Former CMS Policy Officer
  • Barbara Bigelow, MEd, Patient Advocate

This symposium will provide a forward-looking glimpse into the future of nuclear medicine, including some applications that are translating radiopharmaceutical therapy into tools that may be used for simulations to aid physicians in complex treatment planning scenarios and, ultimately, may help to advance personalized medicine. This session will also showcase how GE Healthcare’s (GEHC) global R&D capabilities and robust molecular imaging pipeline are contributing to this rapidly evolving field of science, along with some of the key regulatory hurdles that our industry may face as we move into the future. The presentation also features a patient advocate whose multiple breast cancer misdiagnoses have left her with significant debilitating health issues and dealing with regulatory hurdles.

Presentation Objectives:
1. Discover more about how the Mars shot initiative for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy may bolster research and lead to new treatments. 
2. Learn more about how GEHC’s robust pipeline in nuclear medicine is contributing to the science of nuclear medicine. 
3. Understand the potential impact of recent policy changes and regulatory barriers that could thwart innovations, and the potential impact it may have on patients in accessing these agents.


11:45 am–12:45 pm PDT


Satellite Symposia Session 
Sponsored by Cyclomedica


11:45 am–12:45 pm PDT

Siemens Healthineers Luncheon Symposium  
Sponsored by Siemens Healthineers


Please join Siemens Healthineers at our luncheon symposium during SNMMI 2022. On June 9, we are virtually revealing our latest Symbia™ SPECT/CT. Following the launch, we invite you to join us in person at SNMMI to hear from nuclear medicine professionals working with the new scanner and see how they have modernized their department to maximize clinical results. 

Additionally, Joyce van Sluis, MSc., of University Medical Center Groningen in the Netherlands, will review first experiences using Biograph Vision Quadra™1 PET/CT, including its clinical performance and the research opportunities made possible with this large-axial field of view PET/CT system.

1 Biograph Vision Quadra is not licensed for sale in Canada, in accordance with Canadian Law. Biograph Vision Quadra is not commercially available in all countries. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.


11:45 am–12:45 pm PDT

PSMA: the next frontier in Theranostics - transforming PCa care. Don’t get left behind…
Sponsored by Telix Pharmaceuticals  


Join Renowned Panel of Nuclear Medicine Thought Leaders Moderated by:

Dr. Delphine Chen, Professor of Radiology, Director of Molecular Imaging, Seattle Cancer Care Alliance, University of Washington

Join a renowned panel of Nuclear Medicine thought leaders moderated by Dr. Delphine Chen of the University of Washington to explore how the introduction of PSMA-PET has changed the landscape of Prostate Cancer Management and what lies ahead for PSMA-based Theranostics, including new and advancing therapeutic applications, as it transforms the future of Prostate Cancer Care.


Tuesday, June 14


6:45–7:45 am PDT

Establishing a Theragnostics Program: Practical Considerations
Sponsored by GE Healthcare


Speaker: 
Medhat Osman, MD, PhD, Professor of Radiology & Director of Nuclear Medicine, Saint Louis University, St. Louis, MO USA

Learning objectives:

• Understand the historical background and evolution of theragnostics in NM
• Understand the patient care pathway and high-level patient management
• Recognize the unique staffing and facility needs for a theragnostics program
• Learn about the patient selection and recruitment process for theragnostic treatment
• Discuss taking theragnostic treatment from clinical trials to routine aspect of care
• Appreciate the importance of organ and lesion dosimetry to personalized treatment regimens
• Learn about the associated patient outcomes with experience to date

 

11:45 am–12:45 pm PDT 

Why Now? The New Paradigm and Rising Role of Nuclear Medicine in Alzheimer’s Disease


Faculty:
 Dr James Brewer, University of California San Diego; Dr Sharon Cohen, University of Toronto; Dr Gil Rabinovici, University of California San Francisco

Program Objective: With the increasing understanding of and ability to manipulate the complex networks of amyloid and tau that drive AD, the value of directly visualizing their activity is exponentially rising. Particularly in light of disease modifying therapies for AD becoming a reality, this program is designed to inspire nuclear medicine specialists and others to become more involved in AD and begin to develop the necessary skills to contribute to this growing need.

Accredited by Medical Education Resources (MER) in partnership with EfficientCME. MER designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM.

Supported by an education grant from Lilly.


11:45 am–12:45 pm PDT 

Next Generation SPECT Imaging
Sponsored by Spectrum Dynamics Medical



State-of-the-art digital SPECT and SPECT/CT scanners provide the foundation for the next generation of clinical applications and the shift to routine 3D imaging. Significant improvements in sensitivity, temporal resolution, and energy resolution drive a paradigm shift in workflow and diagnostic capabilities. In this session, clinical users highlight their experience in this digital transformation.

Digital SPECT Technology: Clinical Experience

  • Heather Jacene, MD, Clinical Director, Nuclear Medicine/PET- CT, Dana-Farber Cancer Institute, Assistant Chief of Nuclear Medicine and Molecular Imaging, Brigham and Women’s Hospital 
  • Timothy M. Bateman, MD, Co-Director, Cardiovascular Radiologic Imaging, Mid America Heart Institute
  • Dr. Laetitia Imbert, PhD, Medical Physicist, CHRU Nancy, France
  • Pr. Antoine Verger, MD, PhD, Professor Nuclear Medicine Department, CHRU Nancy, France